Sponsored Content
- Sponsored Content
- Manufacturing
Key Considerations for Maximizing LV and AAV Production in Transient Transfection Workflows
BPI Contributor
May 7, 2021
20 Min View
Date: May 7, 2021
Duration: 20 Min
Already have an account?
Sponsored by Mirus Bio
This webcast features: Leisha Kopp, Applications Scientist, Mirus Bio
Recombinant adenoassociated virus (AAV) and lentivirus (LV) are critical components of gene and cell therapies, which show incredible promise for the treatment of disease. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater. Here, we present:
Optimization strategies for AAV and LV generation in both adherent and suspension HEK 293 cells
LV and AAV enhancers that further increase functional virus titers over previously optimized conditions
How TransIT-VirusGEN® Transfection Reagent and Kits can expand manufacturing capabilities for gene and cell therapies
Just fill out the form below to watch the recorded webcast.
About the Author
You May Also Like
Sponsored Content
Jun 5 - Jun 6, 2024
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More
